



# Policy and Payment Allowance Update for Provider-Purchased Bebtelovimab for Treatment of COVID-19

---

November 11, 2022

Effective for dates of service (DOS) on or after August 15, 2022, the Department of Health Care Services (DHCS) will reimburse pharmacy providers for provider-purchased Bebtelovimab, a monoclonal antibody for the treatment of COVID-19, when dispensed and/or administered in accordance with the Emergency Use Authorization (EUA) requirements and California State Board of Pharmacy (BOP) statutes.

On February 11, 2022, the Food and Drug Administration (FDA) [authorized the emergency use](#) of Bebtelovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients. Since its approval, Bebtelovimab has been supplied free to providers by the federal government, and there has been no reimbursement of the free product.

On August 15, 2022, drug manufacturer Eli Lilly started the [commercial distribution](#) of Bebtelovimab. DHCS will reimburse for provider-purchased products at the pharmacy rate currently defined as the lower of one of the following:

- National Average Drug Acquisition Cost (NADAC) or, when the NADAC is not available, the Wholesaler Acquisition Cost (WAC) plus 0 percent
- Federal Upper Limit (FUL)
- Maximum Allowable Ingredient Cost (MAIC), plus a pharmacy dispensing fee

Providers may have both federally purchased and commercial products in their inventory initially. For DOS on or after August 15, 2022, providers are to only bill DHCS for product reimbursement if a commercially purchased product is used. Providers must not bill for federally purchased free products. Administering providers may bill for administering either type of product as instructed below.

Providers are instructed to check the batch number on the vial. If the batch number is D534422, the product was commercially purchased. Eli Lilly will release more information about future batch numbers.

## Important Billing Instructions

- Dispensing or administering is restricted to the requirements of the EUA and BOP statutes.
- DHCS will not reimburse the drug ingredient cost for products that are federally purchased and supplied free to providers.
- DHCS will reimburse the drug ingredient cost for provider-purchased products at the pharmacy rate currently defined as the lower of one of the following:
  - NADAC or, when the NADAC is not available, the WAC plus 0 percent
  - FUL
  - MAIC
- DHCS will reimburse the professional dispensing fee for either product.
- DHCS will not make separate payment for the preparation of monoclonal antibodies for use by another provider or supplier to specialty pharmacies that prepare the product prior to infusion by another provider.
- DHCS will reimburse the administration/infusion of Bebtelovimab by a qualified provider when billed to DHCS as a medical claim as instructed below.

## Reimbursement of Administration/Infusion Fee

- DHCS will reimburse the administration/infusion of Bebtelovimab by a provider who is enrolled as a COVID-19 immunizer working within their scope of practice when administered consistently with the EUA and BOP statutes.
- Provider must administer monoclonal antibodies in appropriate settings.
- Administering provider must bill separately for reimbursement of the administration fees by submitting the following administration codes to DHCS as a medical claim on a *CMS 1500* form:

- M0222: Intravenous injection, includes injection and post administration monitoring.
- M0223: Intravenous injection, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider based to the hospital during the COVID-19 public health emergency.
- Reimbursement would be at the current Medicare rate, which is published in the [Medi-Cal Rates page](#) in the *Medi-Cal Provider Manual*.

## Product Distribution Information

- Bebtelovimab has become available for purchase from the distributor AmerisourceBergen (ABC) beginning the week of August 15, 2022. Distribution of Bebtelovimab that was purchased by the federal government and distributed to providers through state allocation has ended.
- For details regarding the transition to commercial supply and the timeline for the transition, providers are to refer to [HHS Update: Bebtelovimab Commercial Transition](#).

## Contact Information

You can call the Medi-Cal Rx Customer Service Center (CSC) at 1-800-977-2273, which is available 24 hours a day, 7 days a week, 365 days per year.

For other questions, email Medi-Cal Rx Education & Outreach at [MediCalRxEducationOutreach@magellanhealth.com](mailto:MediCalRxEducationOutreach@magellanhealth.com).